TY - JOUR T1 - <em>In Vitro</em> and <em>In Vivo</em> Anticancer Effects of Destruxin B on Human Colorectal Cancer JF - Anticancer Research JO - Anticancer Res SP - 2735 LP - 2745 VL - 32 IS - 7 AU - YI-PANG LEE AU - CHE-WEI WANG AU - WAN-CHUN LIAO AU - CHIUNG-RU YANG AU - CHI-TAI YEH AU - CHUNG-HUNG TSAI AU - CHI-CHIANG YANG AU - YEW-MIN TZENG Y1 - 2012/07/01 UR - http://ar.iiarjournals.org/content/32/7/2735.abstract N2 - Aim: The study of the anticancer effects of destruxin B (DB) is rare and its anticancer mechanism remains unknown. The aim of this study was to test the in vitro and in vivo anticancer effects of DB, on human HT-29 colorectal cancer (CRC). Materials and Methods: DB was isolated and characterized by high pressure liquid chromatography, electrospray ionization mass spectrometry and 1H-nuclear magnetic resonance spectroscopy. (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the effects of DB on HT-29 cells in vitro. The anticancer effects of DB were investigated in a murine xenograft model of human colon cancer. Results: A significant inhibition of cell viability was observed with DB treatment in time- and dose-dependent manners. DB administered subcutaneously daily at 0.6-15 mg/kg was proven to be safe and effective in inhibiting the growth of CRC cells. Expression of Bax, cleaved poly (ADP-ribose) polymerase and active caspase-3 were observed with DB treatment and the increase in tumor volumes of treated groups were significantly (p&lt;0.05) lower than those of the mock-treated group. Conclusion: DB has potential as a new therapeutic agent against human CRC. ER -